Rigel (RIGL) Q3 2026 Earnings Call Transcript

Rigel reported Q3 2026 net product sales of $72.3 million, up 13% year over year, including $6.6 million from VEPPANU during its first six weeks on the U.S. market; TAVALISSE rose 3% and REZLIDHIA 20%, while GAVRETO fell 11%. The company narrowed full-year revenue guidance to $290 million–$295 million and raised contract revenue guidance to about $35 million, but Q3 net income declined to $13.2 million from $27.9 million and cash and short-term investments were $99.3 million at Sept. 30. Management is targeting a 2027 registrational study for R289 and described early VEPPANU uptake as encouraging, while noting its full-year product-sales guidance excludes VEPPANU.

Analysis

RIGL’s key near-term question is whether VEPPANU can convert promising access and early refill signals into sustained patient demand—not whether six weeks of launch sales can be annualized. The reported adoption metrics are company estimates, and management will not continue providing this level of launch detail; watch subsequent quarterly sales and prescription persistence for independent confirmation. Community uptake could broaden reach beyond academic centers, but also makes payer mix, gross-to-net deductions, and refill durability important swing factors.

The portfolio provides some cushion, not a clean growth floor: TAVALISSE demand remains constructive, REZLIDHIA is growing, and GAVRETO is declining. Management’s claim that VEPPANU is opening accounts for other products is plausible, but should not be credited until those products show measurable incremental demand. The reduced upper end of legacy product-sales guidance and higher contract-revenue estimate also caution against reading total-revenue guidance as proof of broad-based acceleration. Lower cash versus year-end, alongside higher launch and development costs, makes execution and expense discipline relevant even with management expecting full-year profitability.

The main catalyst is R289’s December ASH update: efficacy and transfusion-independence durability matter more than tolerability alone in deciding whether a 2027 registrational program is credible. The company has not disclosed trial design or a success threshold. Longer term, successful execution could diversify growth beyond marketed products, but today R289 remains a high-variance clinical option. Arvinas and Pfizer remain responsible for vepdegestrant studies; do not conflate that partnered program with RIGL’s VEPPANU launch or infer material financial sensitivity without royalty terms.

Key Decisions for Investors

• Avoid chasing RIGL solely on launch anecdotes. Consider a staged, event-driven long only if subsequent quarterly VEPPANU sales demonstrate sustained demand; reduce or exit if refills/prescriptions weaken or gross-to-net pressure offsets volume.
• Treat the December 12 R289 presentation as the 1–3 month catalyst: reassess on efficacy magnitude and duration of transfusion independence, not safety alone. Failure to show durable clinical activity would undermine the 2027 registrational thesis.
• Monitor RIGL cash, operating expense trajectory, and full-year guidance delivery. A material cash draw or guidance shortfall without matching VEPPANU growth would falsify the financial-discipline narrative and increase downside risk.
• No direct trade in ARVN, PFE, or GRFS from this call alone: verify royalty economics and partner-specific sales exposure before attributing meaningful earnings sensitivity.